Why Is TYRA BIOSCIENCES INC (TYRA) Stock Up Today?

TYRA stock is up 15.25% to $28.65 in today’s session, driven primarily by H.C. Wainwright reiterating its Buy rating for the stock. The move comes amid recent developments including a planned conference call to discuss initial clinical results from the SURF302 Phase 2 study. Despite a recent earnings report that missed estimates, the analyst action has spurred renewed investor interest.

What Happened

H.C. Wainwright has reaffirmed its Buy rating for Tyra Biosciences, maintaining a $45 price target. This follows a recent announcement that the company will host a conference call on September 9 to present initial clinical results from its SURF302 Phase 2 study evaluating oral dabogratinib for intermediate-risk non-muscle invasive bladder cancer. The company reported Q2 earnings of $(0.69) per share, which fell short of the $(0.65) estimate. Despite the earnings miss, the analyst reiteration has provided a significant tailwind for the stock.

What The Data Shows

The stock has gained 10.3% over the last eight sessions, moving from $26.22 to $28.92. Intraday activity shows a volatile start, with the stock opening at $28.76 and reaching a high of $28.79 shortly after the market opened. It has since traded down to $28.50, with volume remaining flat at 0.0M shares, matching the 3-month daily average. The stock is currently within its 52-week range of $11.70 to $40.65 and trades with a market cap of $1.7B. The company remains unprofitable, with an EPS TTM of -2.40 and a beta of 0.73.

What To Watch

The key event to monitor is Tyra Biosciences’ scheduled conference call on September 9, where initial clinical results from the SURF302 Phase 2 study will be discussed. Investors will be watching for any positive data that could reinforce the stock’s momentum.